Gurbuz, MustafaAkkus, ErmanSakin, AbdullahUrvay, SemihaDemiray, Atike GokcenSahin, SuleymanSenler, Filiz Cay2025-05-102025-05-1020221941-66281941-663610.1007/s12029-021-00594-12-s2.0-85100518751https://doi.org/10.1007/s12029-021-00594-1https://hdl.handle.net/20.500.14720/7243Sahin, Suleyman/0000-0001-9769-2565; Guven, Deniz Can/0000-0002-6924-9467; Erol, Cihan/0000-0003-3155-8798; Sakin, Abdullah/0000-0003-2538-8569; Ergun, Yakup/0000-0003-4784-6743; Kilickap, Saadettin/0000-0003-1637-7390; Gurbuz, Mustafa/0000-0001-7680-4142; Turker, Sema/0000-0001-9040-7266; Demiray, Atike Gokcen/0000-0003-4397-5468; Sahin, Ahmet Bilgehan/0000-0002-7846-0870Purpose In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab +/- capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. Methods This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab +/- capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. Results About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7-51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2-30). The median PFS of the patients was 12.0 months (95% CI 10.3-13.7), and median OS was 17.4 months (95% CI 15.2-19.5). There were 2 patients with grade 1 cardiotoxicity. Conclusion Trastuzumab maintenance +/- capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer.eninfo:eu-repo/semantics/closedAccessHer2Gastric CancerTrastuzumabChemotherapyMaintenanceArticle532N/AQ328228833538958WOS:000614703600001